Celator Pharmaceuticals Inc. (Nasdaq: CPXX) reported positive results from a Phase 3 trial of VYXEOS to treat patients with high risk acute myeloid leukemia. Shares of the biopharmaceutical more than tripled by leaping $5.82 to $7.50.
Celator Pharmaceuticals reports upbeat study results
March 15, 2016 at 12:56 PM EDT
